Austrian-based OMV says its executive board has decided the company will no longer pursue the sales process for 100 percent of its shares in OMV New Zealand Limited.
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...